{"id":"https://openalex.org/W4244529185","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","title":"367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors","display_name":"367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W4244529185","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0367"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0367","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Luke","raw_affiliation_strings":["UPMC Hillman Cancer Center, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UPMC Hillman Cancer Center, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011851754","display_name":"Filip Janku","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076736008","display_name":"Anthony J. Olszanski","orcid":"https://orcid.org/0000-0001-5276-5898","observed_orcids":["https://orcid.org/0000-0001-5276-5898"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Olszanski","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031115946","display_name":"Kevin Leach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210107114","display_name":"Spring Bank Pharmaceuticals (United States)","ror":"https://ror.org/0106g8w88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210107114"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Leach","raw_affiliation_strings":["Spring Bank Pharmaceuticals, Hopkinton, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Spring Bank Pharmaceuticals, Hopkinton, MA, USA","institution_ids":["https://openalex.org/I4210107114"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016676777","display_name":"Radhakrishnan P. Iyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210107114","display_name":"Spring Bank Pharmaceuticals (United States)","ror":"https://ror.org/0106g8w88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210107114"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Radhakrishnan Iyer","raw_affiliation_strings":["Spring Bank Pharmaceuticals, Hopkinton, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Spring Bank Pharmaceuticals, Hopkinton, MA, USA","institution_ids":["https://openalex.org/I4210107114"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102329109","display_name":"Atif Abbas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210107114","display_name":"Spring Bank Pharmaceuticals (United States)","ror":"https://ror.org/0106g8w88","country_code":"US","type":"company","lineage":["https://openalex.org/I4210107114"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Atif Abbas","raw_affiliation_strings":["Spring Bank Pharmaceuticals, Hopkinton, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Spring Bank Pharmaceuticals, Hopkinton, MA, USA","institution_ids":["https://openalex.org/I4210107114"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A224.1","last_page":"A224"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.885699987411499,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.885699987411499,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.08370000123977661,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.025599999353289604,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyclic-dinucleotides","display_name":"cyclic dinucleotides","score":0.8389999866485596},{"id":"https://openalex.org/keywords/sting-pathway","display_name":"STING pathway","score":0.8230000138282776},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9599999785423279},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-combination-therapy","display_name":"immune checkpoint inhibitor combination","score":0.7039999961853027},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9079999923706055},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6589999794960022},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7889999747276306},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7879999876022339},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8510000109672546},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7960000038146973},{"id":"https://openalex.org/keywords/immune-activation","display_name":"immune activation","score":0.3700000047683716},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6890000104904175},{"id":"https://openalex.org/keywords/head-and-neck-squamous-cell-carcinoma","display_name":"head and neck squamous cell carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6290000081062317},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.6110000014305115},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.3269999921321869}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7522999048233032},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.6014893054962158},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5257076621055603},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4604327082633972},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4351058006286621},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.40357834100723267},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3979640007019043},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39591145515441895},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3661675453186035},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.354034960269928},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.26438117027282715}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0367","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0367","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0367","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3089206438","https://openalex.org/W3090353834","https://openalex.org/W3031521955","https://openalex.org/W2755044537","https://openalex.org/W3033969712","https://openalex.org/W3171059165","https://openalex.org/W3164113406","https://openalex.org/W3013332717","https://openalex.org/W4409067356","https://openalex.org/W3013094053"],"abstract_inverted_index":{"Background":[0],"Activation":[1],"of":[2,5,15,27,48,55,86,89,93,138,148,195,224,270,286,305,307],"the":[3,16,42,155,158,175,217,225,249,308],"Stimulator":[4],"Interferon":[6],"Genes":[7],"(STING)":[8],"pathway":[9,44],"within":[10],"immune":[11,295,312],"and":[12,29,53,77,81,124,180,216,243,268,277,300,310],"tumor":[13,17,56,98,109,114,237],"cells":[14,52,153],"microenvironment":[18],"(TME)":[19],"results":[20],"in":[21,111,128,174,235,251,274,278,294],"durable":[22],"anti-tumor":[23],"effects":[24,285],"via":[25,200,231,292],"induction":[26],"innate":[28],"adaptive":[30],"immunity.":[31],"SB":[32,70,94,106,139,198,255,287],"11285":[33,71,95,107,140,199,256,288],"is":[34],"a":[35],"next-generation":[36],"immunotherapeutic":[37],"cyclic":[38],"dinucleotide":[39],"that":[40],"activates":[41],"STING":[43,90],"leading":[45],"to":[46,97,205],"stimulation":[47],"tumor-resident":[49],"APCs,":[50],"NK":[51],"priming":[54],"antigen":[57],"specific":[58],"CD8+":[59,151],"T":[60,152],"cells.":[61],"In":[62],"preclinical":[63],"studies":[64],"using":[65],"multiple":[66,112],"tumor-derived":[67],"cell":[68,101,296],"lines,":[69],"induced":[72],"cytokines,":[73,299],"such":[74],"as":[75,122,240,260],"IFN-\u03b1":[76],"-\u03b2,":[78],"TNF-":[79],"\u03b1":[80],"others":[82],"consistent":[83],"with":[84,125,130,203,253,280],"engagement":[85],"TBK1":[87],"downstream":[88],"activation.":[91],"Exposure":[92],"directly":[96],"also":[99],"induces":[100],"death":[102],"by":[103],"STING-mediated":[104],"apoptosis.":[105],"reduced":[108],"volumes":[110],"rodent":[113],"models":[115],"when":[116],"administered":[117,197,259,282],"intravenously,":[118],"intraperitoneally":[119],"or":[120,132],"intratumorally,":[121],"monotherapy":[123,261],"amplified":[126],"effect":[127],"combination":[129,252,279],"CTLA-4":[131],"PD-1":[133],"antibodies.":[134],"The":[135],"novel":[136],"properties":[137],"facilitate":[141,146],"systemic":[142],"administration":[143],"which":[144],"may":[145],"trafficking":[147],"newly":[149],"activated":[150],"from":[154],"periphery":[156],"into":[157],"TME.":[159],"Methods":[160],"This":[161],"open-label,":[162],"multicenter":[163],"phase":[164,212],"1/1b":[165],"clinical":[166],"trial":[167],"(NCT04096638)":[168],"will":[169,187,227,257,289],"enroll":[170],"approximately":[171],"110":[172],"patients":[173],"dose":[176,190,214],"escalation":[177],"(Part":[178,183],"1)":[179],"expansion":[181],"cohorts":[182],"2).":[184],"Part":[185,220],"1":[186],"includ":[188],"parallel":[189],"escalations":[191],"evaluating":[192],"ascending":[193],"doses":[194,276],"intravenously":[196],"3+3":[201],"design":[202],"respect":[204],"dose-limiting":[206],"toxicities,":[207],"maximum":[208],"tolerated":[209],"dose,":[210],"recommended":[211],"2":[213,221],"(RP2D)":[215],"pharmacokinetic/pharmacodynamic":[218],"profile.":[219],"Expansion":[222],"Cohorts":[223],"study":[226],"explore":[228],"initial":[229],"efficacy":[230],"overall":[232],"response":[233],"rate":[234],"pre-specified":[236],"types":[238],"(such":[239],"Melanoma,":[241],"Head":[242],"Neck":[244],"Squamous":[245],"Cell":[246],"Carcinoma)":[247],"at":[248],"RP2D":[250],"atezolizumab.":[254],"be":[258,290],"weekly":[262],"on":[263],"Days":[264],"1,":[265],"8,":[266],"15,":[267],"22":[269],"repeated":[271],"28-day":[272],"cycles":[273],"escalating":[275],"atezolizumab":[281],"Q4W.":[283],"Biological":[284],"evaluated":[291],"changes":[293],"types,":[297],"serum":[298],"gene":[301],"expression":[302],"patterns":[303],"indicative":[304],"activation":[306],"peripheral":[309],"TME":[311],"compartments.":[313],"Results":[314],"\u2018N/A\u2019":[315,317],"Conclusions":[316]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2022-05-12T00:00:00"}